![](https://ml.globenewswire.com/media/815f9c91-bb76-4c14-b3e9-0685275600cc/small/junshi-topalliance-logo-png.png)
NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of ...
-- 1st approval of any checkpoint inhibitor in nasopharyngeal carcinoma in the world -- 2nd indication approved for Toripalimab in China SHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation- …